- Home
- IPHA vs SAVA Comparison
IPHA vs SAVA Comparison
Compare IPHA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- SAVA
- Stock Information
- Founded
- IPHA 1999
- SAVA 1998
- Country
- IPHA France
- SAVA United States
- Employees
- IPHA N/A
- SAVA N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- SAVA Health Care
- Exchange
- IPHA Nasdaq
- SAVA Nasdaq
- Market Cap
- IPHA 148.3M
- SAVA 132.3M
- IPO Year
- IPHA 2019
- SAVA N/A
- Fundamental
- Price
- IPHA $1.77
- SAVA $2.62
- Analyst Decision
- IPHA Strong Buy
- SAVA Buy
- Analyst Count
- IPHA 1
- SAVA 3
- Target Price
- IPHA $11.50
- SAVA $111.50
- AVG Volume (30 Days)
- IPHA 42.3K
- SAVA 3.3M
- Earning Date
- IPHA 09-12-2024
- SAVA 02-26-2025
- Dividend Yield
- IPHA N/A
- SAVA N/A
- EPS Growth
- IPHA N/A
- SAVA N/A
- EPS
- IPHA N/A
- SAVA N/A
- Revenue
- IPHA $36,202,722.00
- SAVA N/A
- Revenue This Year
- IPHA N/A
- SAVA N/A
- Revenue Next Year
- IPHA $101.65
- SAVA N/A
- P/E Ratio
- IPHA N/A
- SAVA N/A
- Revenue Growth
- IPHA N/A
- SAVA N/A
- 52 Week Low
- IPHA $1.29
- SAVA $2.23
- 52 Week High
- IPHA $3.51
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- IPHA 46.55
- SAVA 29.65
- Support Level
- IPHA $1.65
- SAVA $2.65
- Resistance Level
- IPHA $1.87
- SAVA $2.78
- Average True Range (ATR)
- IPHA 0.12
- SAVA 0.24
- MACD
- IPHA -0.03
- SAVA 0.55
- Stochastic Oscillator
- IPHA 33.47
- SAVA 38.46
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.